| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 90 | 2026 | 1092 | 10.520 |
Why?
|
| Polymorphism, Single Nucleotide | 77 | 2023 | 863 | 5.450 |
Why?
|
| Vitamin D | 16 | 2023 | 196 | 4.300 |
Why?
|
| Genetic Predisposition to Disease | 60 | 2023 | 734 | 3.900 |
Why?
|
| Vitamin D Deficiency | 10 | 2023 | 107 | 3.810 |
Why?
|
| Genome-Wide Association Study | 38 | 2023 | 423 | 2.790 |
Why?
|
| Genetic Variation | 35 | 2025 | 430 | 2.390 |
Why?
|
| Prostate | 13 | 2026 | 155 | 2.190 |
Why?
|
| Male | 172 | 2026 | 23409 | 2.100 |
Why?
|
| Skin Pigmentation | 10 | 2021 | 23 | 2.030 |
Why?
|
| Humans | 230 | 2026 | 43102 | 1.940 |
Why?
|
| Middle Aged | 111 | 2026 | 12222 | 1.890 |
Why?
|
| Aged | 92 | 2026 | 8214 | 1.830 |
Why?
|
| Genetic Loci | 13 | 2021 | 104 | 1.770 |
Why?
|
| Genotype | 52 | 2024 | 800 | 1.590 |
Why?
|
| Case-Control Studies | 47 | 2024 | 1285 | 1.570 |
Why?
|
| Genetics, Population | 19 | 2025 | 121 | 1.550 |
Why?
|
| Health Status Disparities | 6 | 2024 | 719 | 1.490 |
Why?
|
| Genome, Human | 14 | 2025 | 144 | 1.360 |
Why?
|
| Chromosomes, Human, Pair 8 | 8 | 2016 | 31 | 1.360 |
Why?
|
| Gene Frequency | 31 | 2021 | 206 | 1.320 |
Why?
|
| Prostate-Specific Antigen | 16 | 2024 | 147 | 1.250 |
Why?
|
| Alleles | 19 | 2021 | 352 | 1.220 |
Why?
|
| Breast Neoplasms | 11 | 2025 | 1723 | 1.180 |
Why?
|
| Adult | 73 | 2026 | 13872 | 1.130 |
Why?
|
| Risk Factors | 42 | 2025 | 3994 | 1.130 |
Why?
|
| Healthcare Disparities | 5 | 2024 | 590 | 1.040 |
Why?
|
| Polymorphism, Genetic | 14 | 2016 | 201 | 1.020 |
Why?
|
| Prostatectomy | 8 | 2021 | 70 | 0.970 |
Why?
|
| Chromosome Mapping | 17 | 2018 | 199 | 0.970 |
Why?
|
| Haplotypes | 21 | 2018 | 197 | 0.950 |
Why?
|
| Melanins | 4 | 2021 | 42 | 0.890 |
Why?
|
| Lung Neoplasms | 8 | 2026 | 495 | 0.880 |
Why?
|
| Female | 87 | 2026 | 24698 | 0.840 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 61 | 0.820 |
Why?
|
| Reference Values | 2 | 2024 | 211 | 0.820 |
Why?
|
| Anthropology, Physical | 3 | 2020 | 8 | 0.780 |
Why?
|
| Linkage Disequilibrium | 19 | 2017 | 86 | 0.760 |
Why?
|
| Genetic Markers | 21 | 2013 | 150 | 0.750 |
Why?
|
| Body Mass Index | 6 | 2017 | 925 | 0.740 |
Why?
|
| United States | 36 | 2025 | 5205 | 0.730 |
Why?
|
| Lung | 4 | 2024 | 492 | 0.730 |
Why?
|
| DNA, Mitochondrial | 5 | 2015 | 191 | 0.680 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 259 | 0.660 |
Why?
|
| Receptors, Calcitriol | 5 | 2023 | 69 | 0.640 |
Why?
|
| Promoter Regions, Genetic | 8 | 2012 | 526 | 0.600 |
Why?
|
| Warfarin | 6 | 2017 | 67 | 0.600 |
Why?
|
| Aged, 80 and over | 23 | 2019 | 2853 | 0.590 |
Why?
|
| Colorectal Neoplasms | 7 | 2019 | 512 | 0.580 |
Why?
|
| Biopsy | 7 | 2023 | 177 | 0.580 |
Why?
|
| Anemia, Sickle Cell | 5 | 2021 | 187 | 0.550 |
Why?
|
| Carcinoma | 2 | 2011 | 108 | 0.540 |
Why?
|
| Genomics | 4 | 2024 | 293 | 0.540 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2014 | 100 | 0.520 |
Why?
|
| Anticoagulants | 6 | 2017 | 122 | 0.520 |
Why?
|
| Incidence | 10 | 2025 | 1078 | 0.500 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 65 | 0.490 |
Why?
|
| Models, Genetic | 13 | 2015 | 183 | 0.490 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 174 | 0.490 |
Why?
|
| Early Detection of Cancer | 4 | 2024 | 449 | 0.490 |
Why?
|
| Prognosis | 13 | 2020 | 861 | 0.480 |
Why?
|
| Health Education | 1 | 2019 | 363 | 0.470 |
Why?
|
| Y Chromosome | 4 | 2001 | 55 | 0.470 |
Why?
|
| Zinc | 1 | 2016 | 131 | 0.460 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 989 | 0.460 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 374 | 0.460 |
Why?
|
| Africa, Western | 11 | 2024 | 19 | 0.450 |
Why?
|
| Biomedical Research | 5 | 2025 | 502 | 0.450 |
Why?
|
| Cohort Studies | 19 | 2025 | 1759 | 0.450 |
Why?
|
| Pharmacogenetics | 4 | 2017 | 67 | 0.440 |
Why?
|
| Risk Assessment | 10 | 2023 | 863 | 0.440 |
Why?
|
| Dietary Supplements | 1 | 2016 | 213 | 0.430 |
Why?
|
| Chromosomes, Human, Y | 2 | 2012 | 15 | 0.430 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 376 | 0.430 |
Why?
|
| Germ-Line Mutation | 3 | 2022 | 75 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 367 | 0.430 |
Why?
|
| Genetic Testing | 4 | 2020 | 91 | 0.430 |
Why?
|
| Phylogeny | 5 | 2012 | 769 | 0.410 |
Why?
|
| Multiple Myeloma | 3 | 2020 | 48 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2025 | 968 | 0.400 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 2676 | 0.400 |
Why?
|
| Socioeconomic Factors | 5 | 2024 | 1234 | 0.400 |
Why?
|
| Interleukin-16 | 1 | 2012 | 2 | 0.380 |
Why?
|
| Body Height | 3 | 2021 | 53 | 0.360 |
Why?
|
| Logistic Models | 9 | 2016 | 1009 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 10 | 0.340 |
Why?
|
| DNA Methylation | 5 | 2019 | 403 | 0.340 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3156 | 0.340 |
Why?
|
| Mutation | 11 | 2021 | 1177 | 0.330 |
Why?
|
| Allelic Imbalance | 1 | 2010 | 4 | 0.330 |
Why?
|
| Genes, myc | 1 | 2010 | 31 | 0.330 |
Why?
|
| Duffy Blood-Group System | 2 | 2021 | 5 | 0.330 |
Why?
|
| District of Columbia | 3 | 2020 | 80 | 0.320 |
Why?
|
| Genetic Association Studies | 7 | 2017 | 118 | 0.320 |
Why?
|
| Gene Dosage | 1 | 2010 | 75 | 0.320 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2024 | 59 | 0.320 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 81 | 0.320 |
Why?
|
| Receptors, Estrogen | 4 | 2026 | 183 | 0.320 |
Why?
|
| Retrospective Studies | 9 | 2021 | 2544 | 0.310 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 146 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 220 | 0.300 |
Why?
|
| Odds Ratio | 6 | 2021 | 587 | 0.300 |
Why?
|
| Africa | 8 | 2021 | 82 | 0.290 |
Why?
|
| Smoking | 6 | 2015 | 1024 | 0.290 |
Why?
|
| Risk | 7 | 2019 | 287 | 0.290 |
Why?
|
| Chicago | 5 | 2020 | 31 | 0.290 |
Why?
|
| Endoribonucleases | 1 | 2008 | 25 | 0.290 |
Why?
|
| Europe | 8 | 2021 | 115 | 0.280 |
Why?
|
| Cadherins | 3 | 2014 | 102 | 0.280 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2007 | 26 | 0.270 |
Why?
|
| Membrane Transport Proteins | 3 | 2009 | 100 | 0.270 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2012 | 98 | 0.270 |
Why?
|
| Mixed Function Oxygenases | 2 | 2011 | 31 | 0.270 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2013 | 83 | 0.270 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 27 | 0.270 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 66 | 0.270 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 228 | 0.260 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 638 | 0.260 |
Why?
|
| Receptor, EphB2 | 2 | 2011 | 6 | 0.260 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 81 | 0.260 |
Why?
|
| Membrane Proteins | 4 | 2012 | 561 | 0.260 |
Why?
|
| Glutamine | 3 | 2024 | 36 | 0.250 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 298 | 0.250 |
Why?
|
| Codon, Nonsense | 2 | 2007 | 23 | 0.250 |
Why?
|
| Caribbean Region | 3 | 2013 | 79 | 0.250 |
Why?
|
| Selection, Genetic | 4 | 2014 | 75 | 0.250 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2026 | 3 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 152 | 0.240 |
Why?
|
| Multigene Family | 1 | 2006 | 105 | 0.240 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 83 | 0.240 |
Why?
|
| Algorithms | 6 | 2015 | 509 | 0.240 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2005 | 4 | 0.240 |
Why?
|
| Asthma | 4 | 2017 | 416 | 0.230 |
Why?
|
| Multifactorial Inheritance | 4 | 2023 | 34 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2015 | 760 | 0.220 |
Why?
|
| Glutaminase | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2024 | 20 | 0.220 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2014 | 27 | 0.220 |
Why?
|
| Genetics | 1 | 2004 | 10 | 0.220 |
Why?
|
| Residence Characteristics | 2 | 2025 | 363 | 0.220 |
Why?
|
| Estrogens | 1 | 2026 | 203 | 0.210 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2025 | 47 | 0.210 |
Why?
|
| Melanoma | 2 | 2016 | 110 | 0.210 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 60 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 2 | 2024 | 180 | 0.210 |
Why?
|
| Methylphenidate | 1 | 2024 | 56 | 0.210 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 41 | 0.210 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 89 | 0.200 |
Why?
|
| Isoenzymes | 1 | 2004 | 168 | 0.200 |
Why?
|
| Young Adult | 11 | 2021 | 5080 | 0.200 |
Why?
|
| DNA, Neoplasm | 3 | 2010 | 92 | 0.200 |
Why?
|
| Germ Cells | 2 | 2022 | 74 | 0.200 |
Why?
|
| Principal Component Analysis | 5 | 2019 | 87 | 0.200 |
Why?
|
| Caregivers | 1 | 2026 | 197 | 0.200 |
Why?
|
| Nigeria | 6 | 2012 | 92 | 0.200 |
Why?
|
| Receptors, Corticotropin | 1 | 2003 | 4 | 0.200 |
Why?
|
| Adolescent | 11 | 2024 | 6081 | 0.200 |
Why?
|
| Calcifediol | 1 | 2023 | 17 | 0.200 |
Why?
|
| Carrier Proteins | 3 | 2012 | 321 | 0.200 |
Why?
|
| Monophenol Monooxygenase | 1 | 2003 | 14 | 0.200 |
Why?
|
| Base Sequence | 8 | 2011 | 983 | 0.190 |
Why?
|
| Models, Statistical | 4 | 2014 | 195 | 0.190 |
Why?
|
| Health Personnel | 1 | 2026 | 277 | 0.190 |
Why?
|
| Endonucleases | 2 | 2021 | 18 | 0.190 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2014 | 51 | 0.190 |
Why?
|
| Androgens | 1 | 2023 | 106 | 0.190 |
Why?
|
| DNA Primers | 4 | 2010 | 294 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 186 | 0.190 |
Why?
|
| Inheritance Patterns | 2 | 2016 | 9 | 0.190 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2017 | 32 | 0.180 |
Why?
|
| Phenotype | 8 | 2017 | 780 | 0.180 |
Why?
|
| Regression Analysis | 5 | 2016 | 490 | 0.180 |
Why?
|
| Mitochondria | 2 | 2024 | 523 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 307 | 0.180 |
Why?
|
| Hypertension | 2 | 2020 | 835 | 0.180 |
Why?
|
| Trinucleotide Repeats | 1 | 2001 | 5 | 0.180 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2001 | 10 | 0.180 |
Why?
|
| Evolution, Molecular | 4 | 2014 | 307 | 0.180 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2014 | 161 | 0.180 |
Why?
|
| Indians, North American | 5 | 2007 | 192 | 0.170 |
Why?
|
| Interleukin-18 | 1 | 2021 | 17 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 15 | 0.170 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 101 | 0.170 |
Why?
|
| Geography | 3 | 2012 | 110 | 0.170 |
Why?
|
| Heart Failure | 2 | 2015 | 302 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2024 | 1604 | 0.170 |
Why?
|
| Social Class | 2 | 2020 | 291 | 0.170 |
Why?
|
| Ohio | 1 | 2020 | 18 | 0.170 |
Why?
|
| Oklahoma | 1 | 2020 | 28 | 0.170 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 236 | 0.160 |
Why?
|
| Medicine | 1 | 2021 | 37 | 0.160 |
Why?
|
| Sex Factors | 5 | 2015 | 1028 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 51 | 0.160 |
Why?
|
| Receptors, Androgen | 1 | 2001 | 144 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 32 | 0.160 |
Why?
|
| New York | 1 | 2020 | 93 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2018 | 15 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 539 | 0.160 |
Why?
|
| Cities | 1 | 2020 | 79 | 0.160 |
Why?
|
| Hair Preparations | 1 | 2019 | 2 | 0.160 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 65 | 0.160 |
Why?
|
| Pedigree | 8 | 2011 | 94 | 0.160 |
Why?
|
| HIV Infections | 1 | 2014 | 2586 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1067 | 0.160 |
Why?
|
| Air Pollutants | 1 | 2021 | 130 | 0.150 |
Why?
|
| Jamaica | 2 | 2012 | 11 | 0.150 |
Why?
|
| Alcoholism | 2 | 2003 | 305 | 0.150 |
Why?
|
| Proteomics | 1 | 2022 | 378 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 133 | 0.150 |
Why?
|
| Social Identification | 1 | 2019 | 65 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 27 | 0.150 |
Why?
|
| Isoantibodies | 1 | 2018 | 9 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 34 | 0.150 |
Why?
|
| Point Mutation | 1 | 1999 | 98 | 0.150 |
Why?
|
| Personality | 1 | 1999 | 55 | 0.140 |
Why?
|
| Quality of Life | 1 | 2023 | 616 | 0.140 |
Why?
|
| Selectins | 1 | 2018 | 3 | 0.140 |
Why?
|
| Chemokines | 1 | 2019 | 96 | 0.140 |
Why?
|
| Mass Screening | 4 | 2024 | 541 | 0.140 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 16 | 0.140 |
Why?
|
| Hemoglobins | 2 | 2015 | 113 | 0.140 |
Why?
|
| Microsatellite Repeats | 4 | 2007 | 61 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 29 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 21 | 0.140 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 18 | 0.140 |
Why?
|
| Prostatic Hyperplasia | 2 | 2016 | 32 | 0.140 |
Why?
|
| Health Planning | 1 | 2017 | 16 | 0.140 |
Why?
|
| Hela Cells | 1 | 2019 | 376 | 0.140 |
Why?
|
| DNA Repair | 2 | 2010 | 198 | 0.140 |
Why?
|
| Health Priorities | 1 | 2017 | 25 | 0.140 |
Why?
|
| Agouti Signaling Protein | 3 | 2006 | 3 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 72 | 0.130 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2014 | 26 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2021 | 1600 | 0.130 |
Why?
|
| Trust | 1 | 2019 | 167 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 287 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 178 | 0.130 |
Why?
|
| Survival Analysis | 5 | 2019 | 368 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2017 | 17 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 48 | 0.130 |
Why?
|
| Calcitriol | 1 | 2017 | 32 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 31 | 0.130 |
Why?
|
| Antipsychotic Agents | 2 | 2014 | 80 | 0.130 |
Why?
|
| Obesity | 2 | 2017 | 1151 | 0.130 |
Why?
|
| Urologic Surgical Procedures | 1 | 2016 | 5 | 0.130 |
Why?
|
| Population | 3 | 2009 | 8 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2026 | 2157 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2024 | 1124 | 0.120 |
Why?
|
| Nutrition Assessment | 1 | 2016 | 80 | 0.120 |
Why?
|
| Chromosomes, Human | 2 | 2014 | 37 | 0.120 |
Why?
|
| Organ Size | 1 | 2016 | 170 | 0.120 |
Why?
|
| Procollagen | 1 | 2015 | 4 | 0.120 |
Why?
|
| Forecasting | 2 | 2017 | 136 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 49 | 0.120 |
Why?
|
| Adiposity | 1 | 2017 | 157 | 0.120 |
Why?
|
| Minority Groups | 2 | 2021 | 690 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 22 | 0.120 |
Why?
|
| DNA | 3 | 2015 | 592 | 0.120 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 118 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 80 | 0.120 |
Why?
|
| Calcium | 2 | 2016 | 491 | 0.120 |
Why?
|
| Apolipoprotein B-100 | 1 | 2015 | 7 | 0.120 |
Why?
|
| Uruguay | 1 | 2015 | 2 | 0.110 |
Why?
|
| Naltrexone | 1 | 2015 | 34 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 4 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 515 | 0.110 |
Why?
|
| Finland | 3 | 1999 | 15 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 186 | 0.110 |
Why?
|
| Receptors, Scavenger | 1 | 2014 | 16 | 0.110 |
Why?
|
| Proteins | 1 | 2017 | 382 | 0.110 |
Why?
|
| Genealogy and Heraldry | 1 | 2014 | 5 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2017 | 735 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 21 | 0.110 |
Why?
|
| Amphetamines | 1 | 2014 | 5 | 0.110 |
Why?
|
| Phenprocoumon | 1 | 2014 | 1 | 0.110 |
Why?
|
| Acenocoumarol | 1 | 2014 | 2 | 0.110 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 1542 | 0.110 |
Why?
|
| Mice | 7 | 2024 | 6644 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 166 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 386 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2014 | 12 | 0.110 |
Why?
|
| Glutarates | 1 | 2013 | 4 | 0.100 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 59 | 0.100 |
Why?
|
| Ocular Motility Disorders | 1 | 2013 | 1 | 0.100 |
Why?
|
| Human Genome Project | 2 | 2012 | 7 | 0.100 |
Why?
|
| Kidney | 1 | 2016 | 372 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2015 | 307 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2014 | 93 | 0.100 |
Why?
|
| Receptors, AMPA | 1 | 2013 | 58 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 63 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2015 | 172 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2015 | 575 | 0.100 |
Why?
|
| Animals | 11 | 2024 | 16992 | 0.100 |
Why?
|
| Ghana | 3 | 2022 | 36 | 0.100 |
Why?
|
| Quantitative Trait Loci | 4 | 2016 | 88 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 78 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 291 | 0.100 |
Why?
|
| Aldosterone | 1 | 2013 | 66 | 0.100 |
Why?
|
| Bayes Theorem | 3 | 2008 | 126 | 0.100 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 18 | 0.100 |
Why?
|
| Genetic Research | 2 | 2010 | 11 | 0.100 |
Why?
|
| Overweight | 1 | 2015 | 249 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 291 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 71 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 518 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 125 | 0.090 |
Why?
|
| Cameroon | 1 | 2012 | 35 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 122 | 0.090 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 250 | 0.090 |
Why?
|
| Fathers | 1 | 2012 | 38 | 0.090 |
Why?
|
| Crossing Over, Genetic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2013 | 243 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 706 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 6 | 0.090 |
Why?
|
| Ephrin-B2 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 11 | 0.090 |
Why?
|
| Seasons | 1 | 2012 | 139 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 704 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2012 | 71 | 0.090 |
Why?
|
| Iodide Peroxidase | 1 | 2011 | 40 | 0.090 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 1 | 0.090 |
Why?
|
| Thyroid Hormones | 1 | 2011 | 35 | 0.090 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 11 | 0.090 |
Why?
|
| Age Factors | 3 | 2015 | 1154 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 68 | 0.080 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2010 | 4 | 0.080 |
Why?
|
| Indians, South American | 2 | 2007 | 9 | 0.080 |
Why?
|
| Introns | 2 | 2011 | 79 | 0.080 |
Why?
|
| Internationality | 2 | 2021 | 37 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 224 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 58 | 0.080 |
Why?
|
| Sepsis | 1 | 2011 | 90 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 11 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2024 | 115 | 0.080 |
Why?
|
| Dinucleotide Repeats | 1 | 2009 | 2 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 61 | 0.080 |
Why?
|
| Homozygote | 1 | 2009 | 77 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2007 | 90 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2009 | 83 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2024 | 317 | 0.080 |
Why?
|
| Computer Simulation | 4 | 2014 | 408 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 90 | 0.080 |
Why?
|
| Antiporters | 2 | 2006 | 14 | 0.080 |
Why?
|
| Vestibular Aqueduct | 1 | 2009 | 1 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 355 | 0.080 |
Why?
|
| Hearing Loss | 1 | 2009 | 16 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 183 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2010 | 134 | 0.070 |
Why?
|
| Epidemiologic Studies | 2 | 2005 | 33 | 0.070 |
Why?
|
| Asia | 2 | 2014 | 98 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 375 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2015 | 590 | 0.070 |
Why?
|
| Social Environment | 2 | 2010 | 218 | 0.070 |
Why?
|
| Stem Cell Factor | 1 | 2007 | 8 | 0.070 |
Why?
|
| Health Status | 1 | 2012 | 442 | 0.070 |
Why?
|
| Population Dynamics | 2 | 2014 | 50 | 0.070 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2007 | 6 | 0.070 |
Why?
|
| Neoplasms | 2 | 2017 | 1377 | 0.070 |
Why?
|
| Smegmamorpha | 1 | 2007 | 24 | 0.070 |
Why?
|
| ROC Curve | 2 | 2020 | 159 | 0.070 |
Why?
|
| Deafness | 1 | 2007 | 7 | 0.070 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2007 | 4 | 0.070 |
Why?
|
| Health | 1 | 2007 | 30 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2007 | 21 | 0.070 |
Why?
|
| West Indies | 2 | 2007 | 13 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 17 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 290 | 0.060 |
Why?
|
| History | 1 | 2006 | 1 | 0.060 |
Why?
|
| Economics | 1 | 2006 | 7 | 0.060 |
Why?
|
| Apoptosis | 4 | 2022 | 1568 | 0.060 |
Why?
|
| Chromosome Inversion | 1 | 2006 | 9 | 0.060 |
Why?
|
| Patient Selection | 3 | 2010 | 205 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 14 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 7 | 0.060 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 40 | 0.060 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2006 | 11 | 0.060 |
Why?
|
| Agouti-Related Protein | 1 | 2006 | 10 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2006 | 79 | 0.060 |
Why?
|
| Anxiety | 1 | 2014 | 874 | 0.060 |
Why?
|
| Sudden Infant Death | 1 | 2006 | 7 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 59 | 0.060 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 26 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2008 | 56 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2006 | 93 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2026 | 55 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2006 | 51 | 0.060 |
Why?
|
| Exons | 1 | 2006 | 92 | 0.060 |
Why?
|
| Sodium Channels | 1 | 2006 | 65 | 0.060 |
Why?
|
| Genetics, Medical | 1 | 2005 | 6 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1063 | 0.060 |
Why?
|
| Culture | 1 | 2006 | 172 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2020 | 666 | 0.060 |
Why?
|
| 5' Untranslated Regions | 1 | 2005 | 22 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 934 | 0.060 |
Why?
|
| Southeastern United States | 1 | 2025 | 64 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 455 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 749 | 0.060 |
Why?
|
| Zebrafish Proteins | 1 | 2005 | 55 | 0.060 |
Why?
|
| Gene Expression | 2 | 2021 | 701 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 42 | 0.060 |
Why?
|
| Child | 3 | 2024 | 3443 | 0.060 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2024 | 4 | 0.060 |
Why?
|
| Spain | 3 | 2011 | 44 | 0.060 |
Why?
|
| Calpain | 1 | 2005 | 35 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 1596 | 0.050 |
Why?
|
| Names | 1 | 2004 | 2 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2017 | 10 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2004 | 25 | 0.050 |
Why?
|
| Baltimore | 1 | 2024 | 58 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2024 | 29 | 0.050 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2024 | 5 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 592 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2004 | 12 | 0.050 |
Why?
|
| Zebrafish | 1 | 2005 | 146 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2026 | 452 | 0.050 |
Why?
|
| Body Weight | 1 | 2006 | 429 | 0.050 |
Why?
|
| Ataxia | 1 | 2003 | 8 | 0.050 |
Why?
|
| Metabolomics | 1 | 2024 | 95 | 0.050 |
Why?
|
| Iron Overload | 1 | 2003 | 10 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 22 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 389 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 154 | 0.050 |
Why?
|
| Dystonia | 1 | 2003 | 12 | 0.050 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2003 | 10 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2003 | 35 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 440 | 0.050 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2003 | 17 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 107 | 0.050 |
Why?
|
| Receptors, Melanocortin | 1 | 2003 | 3 | 0.050 |
Why?
|
| Cell Line | 3 | 2015 | 1410 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 223 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 128 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 20 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2023 | 65 | 0.050 |
Why?
|
| Models, Biological | 1 | 2006 | 712 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2023 | 109 | 0.050 |
Why?
|
| Epithelium | 1 | 2022 | 78 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2026 | 574 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 20 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 611 | 0.050 |
Why?
|
| Hydrogels | 1 | 2023 | 59 | 0.050 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 211 | 0.050 |
Why?
|
| Minisatellite Repeats | 1 | 2001 | 18 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2021 | 37 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 186 | 0.040 |
Why?
|
| Acute Disease | 2 | 2015 | 155 | 0.040 |
Why?
|
| Emigration and Immigration | 3 | 2007 | 85 | 0.040 |
Why?
|
| North America | 1 | 2001 | 85 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2001 | 12 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 31 | 0.040 |
Why?
|
| Poverty Areas | 1 | 2021 | 47 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 165 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 116 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2001 | 52 | 0.040 |
Why?
|
| Beauty | 1 | 2020 | 1 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 41 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 12 | 0.040 |
Why?
|
| Men | 1 | 2020 | 19 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 150 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 83 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 465 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 2000 | 9 | 0.040 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2020 | 8 | 0.040 |
Why?
|
| Rural Population | 1 | 2003 | 373 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2019 | 52 | 0.040 |
Why?
|
| Mouth Neoplasms | 1 | 2000 | 60 | 0.040 |
Why?
|
| California | 1 | 2021 | 548 | 0.040 |
Why?
|
| Indians, Central American | 1 | 2019 | 3 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 80 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 92 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 220 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 1180 | 0.040 |
Why?
|
| Exploratory Behavior | 1 | 1999 | 78 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 423 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 532 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 1999 | 70 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2024 | 1455 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 341 | 0.030 |
Why?
|
| Reward | 1 | 1999 | 112 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 213 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2017 | 9 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2009 | 207 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2017 | 3 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2017 | 50 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2017 | 34 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 42 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1999 | 258 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 74 | 0.030 |
Why?
|
| Sputum | 1 | 2017 | 22 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 69 | 0.030 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 1 | 0.030 |
Why?
|
| Anthropometry | 1 | 2017 | 97 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 61 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2017 | 116 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 75 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 64 | 0.030 |
Why?
|
| Inflammation | 2 | 2014 | 758 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 7 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Thrombomodulin | 1 | 2016 | 5 | 0.030 |
Why?
|
| Mexico | 2 | 2007 | 298 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 107 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 147 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 145 | 0.030 |
Why?
|
| Lod Score | 2 | 2007 | 13 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 236 | 0.030 |
Why?
|
| Hemoglobinuria | 1 | 2015 | 4 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mexican Americans | 2 | 2009 | 226 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2015 | 52 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 2015 | 22 | 0.030 |
Why?
|
| Health Policy | 1 | 2017 | 184 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2007 | 267 | 0.030 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2015 | 34 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 48 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 19 | 0.030 |
Why?
|
| History, Ancient | 1 | 2014 | 13 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 80 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 147 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 197 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 178 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 241 | 0.030 |
Why?
|
| Smad7 Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 317 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2019 | 1413 | 0.030 |
Why?
|
| Agriculture | 1 | 2014 | 66 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 60 | 0.030 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2013 | 23 | 0.030 |
Why?
|
| Infant | 2 | 2009 | 1175 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2008 | 333 | 0.030 |
Why?
|
| Markov Chains | 2 | 2004 | 43 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 1070 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2016 | 273 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 127 | 0.030 |
Why?
|
| Metabolome | 1 | 2013 | 51 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 232 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 189 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 118 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Software | 1 | 2014 | 236 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 10 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 27 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 247 | 0.020 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2012 | 9 | 0.020 |
Why?
|
| Receptors, Interleukin | 1 | 2012 | 11 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2012 | 49 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 109 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 123 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2012 | 59 | 0.020 |
Why?
|
| Research | 2 | 2004 | 181 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 31 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 436 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 127 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 97 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 82 | 0.020 |
Why?
|
| Fear | 1 | 2014 | 272 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1271 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 386 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2012 | 114 | 0.020 |
Why?
|
| Critical Illness | 1 | 2011 | 47 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1081 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2010 | 11 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2011 | 120 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2010 | 39 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 104 | 0.020 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 162 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 26 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 223 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 73 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2010 | 128 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2010 | 87 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 288 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2010 | 117 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 97 | 0.020 |
Why?
|
| COS Cells | 1 | 2009 | 68 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 73 | 0.020 |
Why?
|
| Xenopus | 1 | 2009 | 48 | 0.020 |
Why?
|
| Americas | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cotinine | 1 | 2009 | 44 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2008 | 4 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2008 | 13 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 171 | 0.020 |
Why?
|
| San Francisco | 1 | 2008 | 35 | 0.020 |
Why?
|
| Computational Biology | 1 | 2011 | 327 | 0.020 |
Why?
|
| Oocytes | 1 | 2009 | 149 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 296 | 0.020 |
Why?
|
| Melanocytes | 1 | 2007 | 7 | 0.020 |
Why?
|
| Gills | 1 | 2007 | 14 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 48 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 119 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2007 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Pakistan | 1 | 2007 | 20 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2007 | 49 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 719 | 0.020 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2007 | 20 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2010 | 338 | 0.020 |
Why?
|
| Social Problems | 1 | 2007 | 14 | 0.020 |
Why?
|
| Genome, Mitochondrial | 1 | 2007 | 16 | 0.020 |
Why?
|
| Gene Flow | 1 | 2007 | 31 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 760 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2009 | 403 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 549 | 0.020 |
Why?
|
| Mexiletine | 1 | 2006 | 1 | 0.020 |
Why?
|
| Melanosomes | 1 | 2005 | 3 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2006 | 14 | 0.020 |
Why?
|
| Ion Transport | 1 | 2005 | 23 | 0.020 |
Why?
|
| History, 16th Century | 1 | 2005 | 4 | 0.010 |
Why?
|
| History, 17th Century | 1 | 2005 | 5 | 0.010 |
Why?
|
| Genes | 1 | 2005 | 56 | 0.010 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2005 | 33 | 0.010 |
Why?
|
| Alanine | 1 | 2005 | 34 | 0.010 |
Why?
|
| Threonine | 1 | 2005 | 24 | 0.010 |
Why?
|
| Nicotine | 1 | 2009 | 302 | 0.010 |
Why?
|
| Latin America | 1 | 2005 | 55 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2006 | 82 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 110 | 0.010 |
Why?
|
| Language | 1 | 2007 | 185 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 2006 | 228 | 0.010 |
Why?
|
| Chromosomes, Human, X | 1 | 2005 | 23 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 561 | 0.010 |
Why?
|
| Environment | 1 | 2006 | 149 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 416 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 1546 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 195 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2003 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 10 | 0.010 |
Why?
|
| Histidine | 1 | 2003 | 43 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 81 | 0.010 |
Why?
|
| Family Health | 1 | 2004 | 55 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 114 | 0.010 |
Why?
|
| Ferritins | 1 | 2003 | 63 | 0.010 |
Why?
|
| Physical Examination | 1 | 2003 | 45 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2003 | 64 | 0.010 |
Why?
|
| Mucins | 1 | 2003 | 73 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 311 | 0.010 |
Why?
|
| Selection Bias | 1 | 2002 | 13 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 237 | 0.010 |
Why?
|
| Iron | 1 | 2003 | 251 | 0.010 |
Why?
|
| Syntaxin 1 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 249 | 0.010 |
Why?
|
| South Carolina | 1 | 2001 | 25 | 0.010 |
Why?
|
| Methods | 1 | 2000 | 14 | 0.010 |
Why?
|
| Ethanol | 1 | 2003 | 224 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 223 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 12 | 0.010 |
Why?
|
| Mesocricetus | 1 | 2000 | 56 | 0.010 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2000 | 29 | 0.010 |
Why?
|
| Cricetinae | 1 | 2000 | 241 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 638 | 0.010 |
Why?
|
| Carcinogens | 1 | 2000 | 126 | 0.010 |
Why?
|
| Health Surveys | 1 | 2001 | 405 | 0.010 |
Why?
|
| Family | 1 | 2000 | 195 | 0.010 |
Why?
|
| Research Design | 1 | 2001 | 385 | 0.010 |
Why?
|